Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.60 |
| ▸ | SKP1 | P63208 | 2/20 | 0.60 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389069 | 0.93 | SYK (0.53) | CKS1BSKP1SKP2RETSYK | |
| SCHEMBL389068 | 0.93 | SYK (0.53) | CKS1BSKP1SKP2RETSYK | |
| SCHEMBL390147 | 0.93 | SYK (0.53) | CKS1BSKP1SKP2RETSYK | |
| SCHEMBL31370459 | 0.88 | PDE10A (0.50) | CKS1BSKP1SKP2RETSYK | |
| SCHEMBL530038 | 0.87 | CKS1B (0.61) | CKS1BSKP1SKP2RETSYK | |
| SCHEMBL7080374 | 0.87 | CKS1B (0.61) | CKS1BSKP1SKP2RETSYK | |
| SCHEMBL30931884 | 0.87 | CKS1B (0.61) | CKS1BSKP1SKP2RETSYK | |
| SCHEMBL21564581 | 0.87 | CKS1B (0.61) | CKS1BSKP1SKP2RETSYK | |
| SCHEMBL31270899 | 0.87 | MAP4K4 (0.60) | CKS1BSKP1SKP2RETSYK | |
| SCHEMBL23323204 | 0.86 | CKS1B (0.60) | CKS1BSKP1SKP2RETSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246961-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-07-25 | — | — | US | disclosed |
| US-11970493-B2 | Autotaxin inhibitor compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-04-30 | — | — | US | disclosed |
| EP-4225756-A2 | AUTOTAXIN INHIBITOR COMPOUNDS | Ildong Pharmaceutical Co., Ltd. (KR) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022074459-A2 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074459-A2 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106311-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-07 | — | — | US | disclosed |
| WO-2021093720-A1 | PYRAZOLE[1,5-A]PYRIDINE-3-NITRILE COMPOUND AND PHARMACEUTICAL USE THEREOF | 浙江海正药业股份有限公司 | 2021-05-20 | — | — | WO | disclosed |
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-8796244-B2 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | ASTEX THERAPEUTICS LTD (GB) | 2014-08-05 | — | — | US | disclosed |
| CN-103298788-A | Pyridine derivative and medicinal agent | NIPPON SHINYAKU CO LTD | 2013-09-11 | — | — | CN | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20100204187-A1 | Purine Derivatives | PALAU PHARMA, S.A. (ES) | 2010-08-12 | — | — | US | disclosed |
| CN-101589043-A | Purine derivatives | PALAU PHARMA SA (ES) | 2009-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204187-A1 | Purine Derivatives | JAK3, JAK1, JAK2 | CKS1B 424/4885SKP1 3077/4885SKP2 1443/4885 |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ABL1, ERBB2, RET | CKS1B 315/4885SKP1 425/4885SKP2 285/4885 |
| US-20240246961-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, ATXN10, ATXN2L | CKS1B 2876/4885SKP1 3992/4885SKP2 3486/4885 |
| US-20220106311-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, ATXN10, ATXN2L | CKS1B 2876/4885SKP1 3992/4885SKP2 3486/4885 |
| US-11970493-B2 | Autotaxin inhibitor compounds | ENPP2, ATXN10, ATXN2L | CKS1B 2876/4885SKP1 3992/4885SKP2 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.